Moirai Biodesign, a start-up member of CataloniaBio & HealthTech and specialised in the development of RNA-based solutions for new therapies and diagnostic systems has launched MoiRNAiFold, a best-in-class software for the design of complex RNA molecules.
The application of synthetic RNA is very innovative and has great medical and pharmacological potential, as it opens the door to a new generation of targeted therapies for neurological, oncological or neurodegenerative pathologies as well as for the development of new antibiotics and vaccines.
“One of the greatest advantages of synthetic RNA therapeutic approaches is the ability to adapt quickly to new pathogens or diseases. For example, Moderna and Pfizer/BioNtech have developed synthetic mRNA vaccines to induce immunity, winning the race to produce the first vaccines against the new SARS-CoV-2 coronavirus” explains Amadís Pagès, co-founder and CEO of Moirai.
Ivan Dotu, co-founder and CTO of Moirai, says “the design of RNA structures can be substantially improved by using algorithms to predict their stability".
The results of the MoiRNAiFold studies have been published in the Nucleic Acids Research journal, issued by Oxford University.
Photo: Team of Moirai Biodesign at the Barcelona Science Park.
Comments